Additionally, the E3 ubiquitin ligase ubiquitin-conjugating enzyme E2 C (UBE2C) has been shown to ubiquitinate and degrade RyR2 in breast cancer cells, where it inhibits the Wnt/β-catenin signaling pathway [76]. Here, UBE2C is linked to breast cancer.